Extracellular matrix: A functional scaffold

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 3-19

  Theocharis, Achilleas ^a   Gialeli, Chrisostomi ^a   Hascall, Vincent ^b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85120290909     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (53)

1. Alam, N., Goel, H. L., Zarif, M. J., et al. (2007). The integrin-growth factor receptor duet. J Cell Physiol 213, 649-653.
2. Allegretta, M., and Filmus, J. (2011). Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem 1 1, 543-548.
3. Askari, J. A., Buckley, P. A., Mould, A. P., and Humphries, M. J. (2009). Linking integrin conformation to function. J Cell Sci 122, 165-170.
4. Barczyk, M., Carracedo, S., and Gullberg, D. (2010). Integrins. Cell Tissue Res 339, 269-280.
5. Blasi, F., and Sidenius, N. (2010). The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584, 1923-1930.
6. Brew, K., and Nagase, H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803, 55-71.
7. Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., and Ingber, D. E. (1997). Geometric control of cell life and death. Science 276, 1425-1428.
8. Comoglio, P. M., Boccaccio, C., and Trusolino, L. (2003). Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol 15, 565-571.
9. Couchman, J. R. (2010). Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 26, 89-114.
10. Duca, L., Floquet, N., Alix, A. J., Haye, B., and Debelle, L. (2004). Elastin as a matrikine. Crit Rev Oncol Hematol 49, 235-244.
11. Durbeej, M. (2010). Laminins. Cell Tissue Res 339, 259-268.
12. Fears, C. Y., and Woods, A. (2006). The role of syndecans in disease and wound healing. Matrix Biol 25, 443-456.
13. Filmus, J., Capurro, M., and Rast, J. (2008). Glypicans. Genome Biol 9, 224.
14. Frantz, C., Stewart, K. M., and Weaver, V. M. (2010). The extracellular matrix at a glance. J Cell Sci 123, 4195-4200.
15. Gao, Y., Xiao, Q., Ma, H., et al. (2010). LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A 107, 18892-18897.
16. Gebbink, M. F. (2011). Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost 9 (Suppl. 1), 174-181.
17. Gialeli, C., Theocharis, A. D., and Karamanos, N. K. (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
18. Heinegård, D. (2009). Proteoglycans and more - from molecules to biology. Int J Exp Pathol. 90, 575-586.
19. Heino, J. (2007). The collagen family members as cell adhesion proteins. Bioessays 29, 1001-1010.
20. Hildenbrand, R., Allgayer, H., Marx, A., and Stroebel, P. (2010). Modulators of the urokinasetype plasminogen activation system for cancer. Expert Opin Investig Drugs 19, 641-652.
21. Iozzo, R. V., and Schaefer, L. (2010). Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
22. Iozzo, R. V., Zoeller, J. J., and Nystrom, A. (2009). Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 27, 503-513.
23. Karamanos, N. K., and Tzanakakis, G. N. (2012). Glycosaminoglycans: from "cellular glue" to novel therapeutical agents. Curr Opin Pharmacol 12, 220-222.
24. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
25. Kim, S. H., and Kim, S. H. (2008). Antagonistic effect of EGF on FAK phosphorylation/dephosphorylation in a cell. Cell Biochem Funct 26, 539-547.
26. Kim, S. H., Turnbull, J., and Guimond, S. (2011). Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 209, 139-151.
27. Kirkpatrick, C. A., and Selleck, S. B. (2007). Heparan sulfate proteoglycans at a glance. J Cell Sci 120, 1829-1832.
28. Kolset, S. O., and Pejler, G. (2011). Serglycin: a structural and functional chameleon with wide impact on immune cells. J Immunol 187, 4927-4933.
29. Lambaerts, K., Wilcox-Adelman, S. A., and Zimmermann, P. (2009). The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol 21, 662-669.
30. LeBleu, V. S., MacDonald, B., and Kalluri, R. (2007). Structure and function of basement membranes. Exp Biol Med 232, 1121-1129.
31. Levental, K. R., Yu, H., Kass, L., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906.
32. Li, X. J., Ong, C. K., Cao, Y., et al. (2011). Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71, 3162-3172.
33. Manon-Jensen, T., Itoh, Y., and Couchman, J. R. (2010). Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 3876-3889.
34. Misra, S., Heldin, P., Hascall, V. C., et al. (2011). Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278, 1429-1443.
35. Moser, M., Legate, K. R., Zent, R., and Fassler, R. (2009). The tail of integrins, talin, and kindlins. Science 324, 895-899.
36. Muiznieks, L. D., Weiss, A. S., and Keeley, F. W. (2010). Structural disorder and dynamics of elastin. Biochem Cell Biol 88, 239-250.
37. Murphy, G. (2008). The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8, 932-941.
38. Obermajer, N., Jevnikar, Z., Doljak, B., and Kos, J. (2008). Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res 49, 193-196.
39. Pankov, R., and Yamada, K. M. (2002). Fibronectin at a glance. J Cell Sci 115, 3861-3863.
40. Patarroyo, M., Tryggvason, K., and Virtanen, I. (2002). Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 12, 197-207.
41. Rocks, N., Paulissen, G., El Hour, M., et al. (2008). Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90, 369-379.
42. Rozario, T., and DeSimone, D. W. (2010). The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol 341, 126-140.
43. Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12, 697-715.
44. Skandalis, S. S., Labropoulou, V. T., Ravazoula, P., et al. (2011). Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 11, 314.
45. Skliris, A., Happonen, K. E., Terpos, E., et al. (2011). Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur J Immunol 41, 437-449.
46. Smith, H. W., and Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11, 23-36.
47. Tadokoro, S., Shattil, S. J., Eto, K., et al. (2003). Talin binding to integrin beta tails: a final common step in integrin activation. Science 302, 103-106.
48. Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N., and Karamanos, N. K. (2010). Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
49. Ulisse, S., Baldini, E., Sorrenti, S., and D'Armiento, M. (2009). The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9, 32-71.
50. Vogel, W. F., Abdulhussein, R., and Ford, C.E. (2006). Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 18, 1108-1116.
51. Wang, A., de la Motte, C., Lauer, M., and Hascall, V. (2011). Hyaluronan matrices in pathobiological processes. FEBS J 278, 1412-1418.
52. Whitelock, J. M., Melrose, J., and Iozzo, R. V. (2008). Diverse cell signaling events modulated by perlecan. Biochemistry 47, 11174-11183.
53. Zoller, M. (2011). CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11, 254-267.